Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma.
We herein report a female child with choroid plexus carcinoma treated with standard dose of imatinib at disease recurrence. This patient failed initial twice-surgical resections, central nervous system (CNS) irradiation, and adjuvant chemotherapies and high-dose thiotepa and melphalan with auto peripheral blood stem cell rescue. Finally, imatinib treatment was undergone as a palliative setting, however the tumor did not reduce and the patient died of tumor bleedings. We consider that the reasons for the failure are as follows: i) adequate CNS level of imatinib were not obtained because of the blood brain barrier, ii) the lack of platelet-derived growth factor receptor beta expression in our case may have a crucial role.
Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan;
Chihiro
C
Kawakami
Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan;
Akiko
A
Inoue
Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan;
Kimitaka
K
Takitani
Department of Pathology, Osaka Medical College, Takatsuki, Osaka, Japan;
Motomu
M
Tsuji
Department of Laboratory Medicine, Gunnma Childrens' Medical Center, Shibukawa, Gunnma, Japan.
Kimiko
K
Wakai
Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan;
Hiroshi
H
Tamai
choroid plexus carcinoma.; imatinib mesylate; platelet derived growth factor receptor (PDGFR) alfa